Jupiter Neurosciences Starts Phase 2a Parkinson’s Trial, JOTROL™ Shows Ninefold Bioavailability
JUNS•Jupiter Neurosciences has begun enrolling 30 patients across three centers in its randomized, double-blind Phase 2a RESET trial of JOTROL™ for Parkinson’s disease, with first dosing expected soon. JOTROL™ demonstrated roughly ninefold higher plasma bioavailability (Cmax 455 ng/mL vs. 85 ng/mL) in Phase 1 and targets disease-modifying mechanisms.
1. Phase 2a Enrollment Commences
Jupiter Neurosciences has initiated patient enrollment in its Phase 2a RESET trial (NCT07592767) for JOTROL™, targeting 30 Parkinson’s disease patients randomized 1:1:1 to two dose levels or placebo across three U.S. centers. First patient dosing is anticipated in the near term as the company advances its lead investigational candidate.
2. JOTROL™ Profile and Phase 1 Results
JOTROL™ is an investigational trans-resveratrol micellar formulation designed to enhance CNS exposure and address oxidative stress, mitochondrial dysfunction and chronic neuroinflammation. In a 24-subject Phase 1 trial, it achieved a Cmax of 455 ng/mL versus 85 ng/mL for conventional resveratrol and showed measurable CSF levels with no serious adverse events.
3. Parkinson’s Disease Market Opportunity
Parkinson’s disease affects an estimated 1.1 million U.S. patients with roughly 90,000 new diagnoses annually, carrying an $82.2 billion annual economic burden. The global PD treatment market was valued at $5.65 billion in 2024 and is projected to grow to $7.58 billion by 2030 at a 5.0% CAGR, with no approved disease-modifying therapies to date.
4. Trial Design and Timeline
The RESET study is a multi-center, randomized, double-blind, placebo-controlled Phase 2a trial evaluating safety, tolerability and pharmacokinetics (plasma and CSF) of JOTROL™ over 12 weeks. Secondary endpoints include ATP and inflammatory biomarkers, with projected study completion in the first half of 2027.
